// App-Quantinova.ai

S201 : EFFICACY AND SAFETY OF AVAPRITINIB IN PATIENTS WITH ADVANCED SYSTEMIC MASTOCYTOSIS: INTERIM RESULTS FROM THE OPEN-LABEL, SINGLE-ARM, PHASE 2 PATHFINDER STUDY

Researchers

Presenter

  • Andreas Reiter

Principal Investigators

  • Deepti Radia

  • Michael W. Deininger

  • Tracy I. George

  • Jens Panse

  • Alessandro M. Vannucchi

  • Madlen Jentzsch

  • Ivn Alvarez-Twose

  • Andrzej Mital

  • Olivier Hermine

  • Ingunn Dybedal

  • Elizabeth O. Hexner

  • Lisa K. Hicks

  • Lambert Span

  • Ruben Mesa

  • Prithviraj Bose

  • Kristen M. Pettit

  • Mark L. Heaney

  • Stephen Oh

  • Jayita Sen

  • Hui-Min Lin

  • Brenton G. Mar

  • Jason Gotlib

Medical Centers

  • Leipzig University, Leipzig, Germany

  • University of Texas MD Anderson Cancer Center, Houston, Texas, United States

  • Institute of Mastocytosis Studies of Castilla-La Mancha, Spanish Reference Center of Mastocytosis,Toledo,Spain

  • St Michael's Hospital, University of Toronto, Toronto, ON, Canada

  • University of Utah-Huntsman Cancer Institute, Salt Lake City, UT

  • Stanford Cancer Institute, Stanford University School of Medicine, Stanford, CA

  • Medical University of Gdansk, Gdansk, Poland

  • Abramson Cancer Center, University of Pennsylvania, Philadelphia, Pennsylvania, United States

  • Dana-Farber Cancer Institute, Boston, MA, United States

  • Oslo University Hospital, Oslo, Norway

  • Guy's And St Thomas NHS Foundation Trust, London, United Kingdom

  • Mays Cancer Institute at UT Health San Antonio MD Anderson,San Antonio,United States

  • Necker–Enfants Malades Hospital and Imagine Institute, CEREMAST,Paris,France

  • University Medical Center, University of Groningen, Groningen, Netherlands

  • Guy's &amp

  • Center of Research and Innovation of Myeloproliferative Neoplasms (CRIMM), Azienda Ospedaliera-Universitaria Careggi, Florence, Italy

  • University Hospital Mannheim, Heidelberg University, Mannheim, Germany

  • Columbia University, New York, New York, United States

  • University Hospital RWTH Aachen, Aachen, Germany

  • Blueprint Medicines,Cambridge,United States

  • Alvin J. Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine, St. Louis, MO

  • ARUP Laboratories, University of Utah, Salt Lake City, UT

  • The University of Michigan, Ann Arbor, Michigan, United States

Locations

  • Germany

  • United States

  • Spain

  • Canada

  • Poland

  • Norway

  • United Kingdom

  • France

  • Netherlands

  • Italy

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

  • Gastroenterology (GU)

  • Autoimmune (AI)

Disease

  • Myeloid neoplasms

  • Mastocytosis

Biomarkers

  • N/A

Drug/Treatment

  • Midostaurin

Outcome

  • N/A

Study Design

  • Open Label

  • Single Arm

  • Multinational

Phase

  • II

Study Id's

  • NCT02561988

  • NCT03580655

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved